The Russian government will start to limit the participation of foreign drugs in the public procurement and state tenders since the second half of the current year, according to recent statements of Arkady Dvorkovich, Russia’s Deputy Prime Minister.
Mr Dvorkovich said that imported drugs will not be the subject of public procurement in the case of the presence of two or more domestic analogues during the tender process, while the norm will apply only to those drugs from the list of vital medicines.
At the same time the norm will not apply to pharmacies that will continue drug purchases without any limitations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze